Background The sequelae of myocardial infarction (MI) require specific pharmacological
therapy to minimise the post-MI remodelling, which in many cases evolves into …

Background and purpose Oral anticoagulation prevents thromboembolism in atrial
fibrillation. Factor Xa inhibitors, like edoxaban, are known to reduce inflammation and …

Background: Direct-activated factor X (FXa) plays an important role in thrombosis and is also
involved in inflammation via the protease-activated receptor (PAR)-1 and PAR-2 pathway …

Introduction Rivaroxaban selectively inhibits factor Xa (FXa), which plays a central role in
blood coagulation. In addition, FXa activates protease-activated receptor-2 (PAR-2). We …

Objectives Rivaroxaban has been shown to reduce overall death from cardiovascular
causes in patients with recent acute coronary syndrome. Therefore, we evaluated the …

Background Heart failure (HF) is considered to be a prothrombotic condition and it has been
suggested that coagulation factors contribute to maladaptive cardiac remodelling via …

Adverse effects of drugs are one of the objective criteria used for choosing the most
appropriate anticoagulant. It is worrying that warfarin may be involved in the progression of …

Aim: A direct oral anti-coagulant, FXa inhibitor, has been applied to the clinical treatment of
myocardial infarction (MI). Experimental studies in mice indicated that FXa inhibitors …

Objective: Selective cyclo-oxygenase-2 (COX-2) inhibitors have been shown to preserve
hemodynamic performance in experimental models of acute myocardial infarction (AMI) in …

Background The rat infarct model was used extensively to study the pathophysiology of
myocardial infarction and to evaluate different therapies. Transthoracic echocardiography is …